The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. IXICO's Revenue for the
six
months ended in Mar. 2026 was $5.27 Mil. IXICO's average Accounts Receivable for the
six
months ended in Mar. 2026 was $2.43 Mil.
Hence, IXICO's Receivables Turnover for the
six
months ended in Mar. 2026 was 2.17.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
IXICO Receivables Turnover Related Terms
IXICO Receivables Turnover Historical Data
* Premium members only.
The historical data trend for IXICO's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHYOF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, IXICO's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IXICO Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IXICO's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where IXICO's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IXICO (PHYOF) has a Receivables Turnover of 2.17 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IXICO and its competitors. According to the industry distribution chart, IXICO ranks #516 out of 839 companies in the Biotechnology industry, placing it in the top 61.5%.
Is IXICO's Receivables Turnover too high?
IXICO's current Receivables Turnover is 2.17. The Biotechnology industry median Receivables Turnover is 5.27. IXICO's value of 2.17 is 58.8% below this industry median. Based on the distribution chart, IXICO ranks #516 out of 839 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IXICO has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does IXICO's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IXICO ranks #516 out of 839 companies for Receivables Turnover. This places IXICO in the lower half of its industry. The industry median Receivables Turnover is 5.27. IXICO's value of 2.17 is 58.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IXICO's current Receivables Turnover of 2.17 is 58.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IXICO and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IXICO's current Receivables Turnover is 2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IXICO stock overvalued right now?
IXICO (PHYOF) has a current Receivables Turnover of 2.17. The stock's GF Value™ is $0.07, compared to a current price of $0.07 — trading right at its estimated fair value. The current Receivables Turnover is 2.17 and 58.8% below the Biotechnology industry median of 5.27. IXICO's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For IXICO (PHYOF), the current Receivables Turnover is 2.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IXICO (PHYOF) Overvalued in 2026?
Based on GuruFocus' analysis, IXICO stock appears to be undervalued.
The current stock price of $0.07 is trading 0% below its estimated GF Value™ of $0.07.
Key valuation signals for PHYOF:
Receivables Turnover: 2.17
GF Value™: $0.07 vs. price of $0.07 (0% below fair value)
Industry Position: 58.8% below the Biotechnology median (#516 of 839)
No single metric tells the full story. See the PHYOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.
42GF Score
Get the complete analysis for PHYOF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHYOF has been successfully added to your 
